A carregar...
Nanoformulations of Anticancer FGFR Inhibitors with Improved Therapeutic Index
Fibroblast growth factor receptor (FGFR) inhibitors like ponatinib and nintedanib are clinically approved for defined cancer patient cohorts but often exert dose-limiting adverse effects. Hence, we encapsulated FGFR inhibitors ponatinib, PD173074, and nintedanib into polylactic acid nanoparticles an...
Na minha lista:
| Publicado no: | Nanomedicine |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7611408/ https://ncbi.nlm.nih.gov/pubmed/30121385 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.nano.2018.08.001 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|